Information Provided By: 
Fly News Breaks for April 20, 2018
DPLO
Apr 20, 2018 | 08:59 EDT
After spending a day with Diplomat Pharmacy management, Lake Street analyst Brooks O'Neil says industry conditions are "extremely favorable." While investor uncertainty has the shares "in limbo," the sentiment should shift in the near term as the company delivers solid fundamental execution, O'Neil tells investors in a research note. He believes Diplomat's recent management changes and acquisitions have strengthened the company and created an opportunity for outperformance. The analyst keeps a Buy rating on the shares with a $35 price target.
News For DPLO From the Last 2 Days
There are no results for your query DPLO
